European Medicines Agency's CHMP recommends approval of Sobi's efanesoctocog alfa for haemophilia A treatment.

STOCKHOLM's Sobi® announced a positive opinion from the European Medicines Agency's CHMP, recommending approval of efanesoctocog alfa for haemophilia A treatment. The once-weekly therapy offers sustained factor VIII levels, improving protection from bleeds compared to existing prophylaxis. The decision will be submitted to the European Commission for a final decision.